Next Phase Newsletter

A leading healthcare investment firm, with multi-billion in assets under management invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. The firm seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. The firm’s team of over 100 professionals is based in USA, Asia, the Middle East, and other key global markets.

The firm invests in all modalities and indications across therapeutics, devices, diagnostics, and digital health, and have no specific preference for technology type.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established investment funding arm of a USA-based health system, one of the largest non-profit health systems in the USA is actively seeking new partnering opportunities. The firm’s objectives include fostering the commercialization of internal ideas as well as external innovation. To date, the firm has been focusing in Series A to B rounds but expect to look into more early-stage opportunities in the future. Initial size of investment can range from $500K – 1M. The firm invests off balance sheet and has no dedicated fund. The firm is focused on partnering and investing in companies based in the USA.

The firm is interested in piloting and investing in technologies that strategically align with the interests of a large integrated delivery network. This includes both the organization’s existing priority areas, along trying to improve the firm’s strategic position in the future. Areas of interest include improving the ratings and member retention in our Medicaid and Medicare Advantage insurance plans, recruiting and retaining clinicians, process optimization, the coming consumerization of healthcare, back-office optimization, and more. The firm is primarily looking for digital health solutions, but will consider some 510k medical devices. The firm is not interested in therapeutics or diagnostics.

The firm has no specific company or management team requirements. The firm prefers to co-invest alongside syndicate partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A $1.2B AUM Seed through Series B venture firm based in the US typically invests between $500K to $20M. The firm focuses on two thematic areas – healthcare and enterprise SaaS. Within healthcare, the firm will invest in digital health, therapeutics, diagnostics and software-enabled medical devices. While somewhat flexible in stage, the firm prefers to have some POC for companies they invest in, such as some in vivo data, at least one hit for drug discovery, and a viable product/prototype for digital health and medical devices. The firm invests primarily in the US, but will invest in Canada as well.

Within healthcare, the firm invests in transformational technologies in all sectors. In therapeutics, the firm has an interest in cell & gene therapy and tissue engineering, but will invest in any modality if the technology is first-in-class. For small molecules or biologics, the firm does not invest in single assets. When investing in medical devices, the firm looks for those where software is a key component of the device. The firm invests in diagnostics and digital health as well, interested in technologies such as AI/ML technologies, drug discovery models, tech enabled services and data infrastructure, among others.

For later stage companies, the firm has no specific requirements. For seed stage companies, the firm is an active investor, and leads in most of their investments, taking a board seat. The firm is interested in companies with strong management teams, having strong expertise in the industry in which the startup is based.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with USA and Europe offices is actively seeking investment opportunities within life sciences and healthcare sectors, with a focus on early stage. Initial investments can range from $100K – 3M, and largely varies by deal. The firm typically invests in the form of equity, and may take less equity in exchange for preemptive or pro-rata rights. The firm will consider global opportunities, but focuses on USA and Europe-based companies.

The firm is interested in various opportunities within therapeutics, devices, diagnostics, and digital health. In therapeutics, the firm is excited about platform technologies (especially in oncology), DNA repair, and novel drug delivery mechanisms. Within devices, technologies that integrate or combine new technologies such as robotics, smart devices, IoT, and imaging are areas of interest. In diagnostics, point of care diagnostics technologies that can substantially transform the current standard of care are of interest. Lastly, within digital health, the firm is interested in telehealth, novel digital interventions, and any technology that successfully leverages AI to improve patient outcomes and clinical workflow. The firm is mostly stage and indication agnostic, but tend to stray away from cardiovascular and CNS indications.

The firm has no specific company or management team requirements. The firm seeks to be a very active, hands-on investor and can support their portfolio companies on their operations, scalability, regulatory strategy, and more. The firm has a growing advisory board that companies can seek to leverage. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science venture capital firm with offices in Western Europe and USA is investing from its third fund that typically makes equity investment into early-stage life science companies. The typical investment size ranges from €10 million-15 million. The third fund is looking to make 10 investments.

The firm is currently looking for new investment opportunities in the life science space. The firm focuses on Therapeutics and Medical Devices sectors. The firm is very opportunistic in terms of subsectors and indications and is most interested in product-focused companies at pre-clinical / clinical stages of development.

The firm primarily invests in private companies with experienced management teams, but has the ability to also consider public companies, depending on the opportunity. The firm seeks to take a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm is seeking to invest in Seed to Series A companies. The firm expects to make most of their investments in North America, but has a global outlook and has evaluated opportunities from other geographies.

Within life sciences, the firm is most interested in digital health technologies, including Digital Therapeutics, AI-powered healthcare solutions, smart devices, and tech enabled services. The firm will be extremely selective about medical device companies without a digital component. The same applies for traditional therapeutics and diagnostics sectors as well. The firm likes to see early traction (i.e. paying customer engagement), but is open to pre-revenue companies.

The firm is open to working with all kinds of management teams. The firm is capable of leading seed rounds and can act as either lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A philanthropic venture firm was established by a family trust to accelerate the development of promising technologies for the diagnosis and treatment of cardiovascular and neurovascular disease through targeted investments. This US-based firm makes 4-5 investments each year of approximately $1-2 million into privately-held companies worldwide at both the seed and Series A stages. The firm operates under an evergreen structure and has made 49 investments to date.

While the firm is focused on cardiovascular, neurovascular and metabolic diseases (e.g., diabetes, dyslipidemia and obesity), The firm invests across all technology sectors including biotech, medtech, diagnostics, and regenerative medicine. The firm looks to invest in companies where its investment will help move the company to a value inflection point necessary for the next and larger financing round.

The firm invests in technologies that have the potential for a clear impact on patient therapy and/or standard of care, an adequate level of IP protection, well-defined use of proceeds with quantifiable and achievable milestones, and a clear understanding of the next round of fundraising needs including size and likely sources.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.